

Special Issue

Shock Syndromes: Pathophysiology, Diagnostics and Emerging Therapeutics Across the Clinical Spectrum

Message from the Guest Editors

Shock, as a life-threatening condition characterized by inadequate tissue perfusion and cellular oxygenation, remains a major challenge in acute and critical care medicine. This Special Issue will provide a comprehensive overview of shock syndromes, spanning the entire clinical spectrum from septic and cardiogenic to hypovolemic and obstructive shock, as well as mixed or less commonly studied forms. We invite original research articles, reviews, and clinical studies that explore underlying pathophysiological mechanisms, novel diagnostic tools including imaging and biomarkers, and innovative therapeutic approaches such as targeted pharmacologic strategies, mechanical circulatory support, and immunomodulation. Special emphasis will be given to precision medicine, translational research, and artificial intelligence applications that may reshape shock management. Through this Special Issue, we will bridge the gap between basic science and clinical practice, enhancing our understanding of shock syndromes and paving the way for improved patient outcomes.

Guest Editors

Dr. George E. Zakynthinos

3rd Department of Cardiology, "Sotiria" Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Dr. Evangelos Oikonomou

3rd Cardiology Department, "Sotiria" Chest Disease Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Deadline for manuscript submissions

31 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/246590

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).